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Abstract 
The goal of drug delivery is to ensure that therapeutic molecules reach the intended target organ 
or tissue such that the effectiveness of the drug is maximized. The efficiency of a drug delivery 
system greatly depends on the choice of drug carrier. Recently, there has been growing interest 
in using micro and nanofibers for this purpose. Reasons for this growing interest include these 
materials’ high surface area to volume ratios, ease of fabrication, high mechanical properties, and 
desirable drug release profile. Here, we review developments in using these materials made by 
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the most prevalent methods of fiber fabrication: electrospinning, microfluidics, wet spinning, 
rotary spinning, and self-assembly for drug delivery purposes. Additionally, we discuss the 
potential to use these fiber based systems in research and clinical applications.  
Keywords: Drug delivery, micro and nanofiber fabrication, microfluidics, electrospinning, wet 
spinning, rotary spinning, self-assembly 
1. Introduction 
Since the beginning of the 20th Century, efficient drug delivery has been a topic of continuous 
study and research. Regardless of developments in areas such as cancer therapeutics and drug 
delivery, progress in certain aspects of each area has been dampened by the inefficiency of the 
carriers used in these drug delivery systems. The importance of the drug carrier can be attributed 
to four factors, which are (i) targeting of the drug to the intended organ for maximum effect, (ii) 
evasion of the immune system of the body to reach the final target, (iii) retention of the 
therapeutic molecules from the preparation and processing to the final target of the drug, and (iv) 
release of the drug molecules at the destination organ such that the molecules can exert the 
intended therapeutic effect. Therefore, the success of an extant or potential application of a drug 
delivery system innately depends on the choice of the drug carrier.1-4  
Researchers have considered numerous carriers over the past few decades,5, 6 and micro 
and nanofibers have become an attractive prospective carrier option.7-13 This could be attributed 
to both the nature of the material used to fabricate the fiber and the nature of this very fabrication 
process. Additionally, the low initial burst rate compared to spherical vesicles and the controlled 
zero-order drug release profile, seen in drug loaded fibers, make them more suitable for drug 
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delivery applications.14-16 Materials such as alginate and gelatin used to fabricate these fibers are 
biocompatible,17, 18 thus causing no harm to the tissue of the host. Such fibers are also 
biodegradable and do not accumulate in the human body disrupting its biochemical and 
physiological processes. Furthermore, these materials exhibit low immunogenicity. This means 
that they do not provoke major immune responses from the host’s immune system. As a result, 
fibers composed of such biomaterials help create effective carriers of therapeutic molecules. 
 The morphology of the fibers makes them ideal candidates for drug delivery systems. By 
virtue of the cylindrical shape of the fibers, they possess a high surface area to volume ratio.7, 19 
This provides the fibers the ability to release the drug into the medium over a large surface area. 
Furthermore, unlike spherical vesicles, where the surface area to volume ratio can only be 
controlled by varying the radius, both the length and the cross-sectional radius can be varied in 
fibers. This adjustability is vital for a drug delivery system in applications that the functional 
parameters are to be precisely controlled. Additionally, several applications of drug delivery 
systems are seen where the drug delivery function occurs alongside a structural role. Tissue 
scaffolds, wound dressings, and other tissue engineering applications can be cited as prime 
examples of such applications.7, 20 For these roles, the shape and mechanical properties of micro 
and nanofibers, composed of biomaterials, are essential. The shape and arrangement of such 
fibers could be easily changed, which makes them more suitable for drug delivery systems than 
micro and nano vesicles. Fibers with different shapes and structures, such as hollow, flat, and 
ribbon shaped, can also be fabricated depending on the intended application.21-23 
Various methods have been used for the fabrication of these micro and nanofibers over 
the past few decades. Wet spinning, rotary spinning, electrospinning, microfluidic fiber 
fabrication, and self-assembly are the most common methods. These five approaches are 
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schematically depicted in Figure 1. Moreover, variants of these methods have been developed to 
cater to the needs of different applications. Among these methods, electrospinning and 
microfluidic fiber fabrication approaches are predominantly employed in research related to drug 
delivery. Each of these methods have some advantages that make them especially suitable for 
specific drug delivery applications.  
 The purpose of this review is to categorize research developments in employing micro 
and nanofibers for drug delivery application. The different fiber fabrication techniques are 
reviewed and further innovations in fiber based drug delivery systems are discussed. For 
example, in discussing microfluidic fiber fabrication for drug delivery applications, structural 
developments, incorporation of stimuli responsive properties, and innovations in the fabrication 
methodology were explored in detail. Furthermore, special emphasis is given to the potential 
applications of these approaches in clinical practice. Finally, each of the applications are 
described in detail and tabulated to obtain a general overview of fibers utilized for drug delivery 
purposes.  
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Figure 1 Most common methods used to fabricate fibers for drug delivery. (a) Illustration 
depicting the incorporation of drug molecules into a microfiber. (b) Schematic of the 
microfluidic fiber fabrication approach. The manner in which the sheath and the core fluid flows 
are directed by micro channels to generate the fiber is depicted.24 (c) Schematic of fiber 
fabrication by electrospinning. The electrically ground plate collects the fiber.25 (d) Rotary 
spinning method where the solution is spun at the high speeds and the centrifugal force causes 
the solvent to evaporate, which results in fiber fabrication.26 (e) Schematic of the building units 
which contribute to the formation of self-assembled nanofibers.27 (f) Wet spinning method, 
where the fibers are injected into a coagulation bath.28 
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2. Microfluidic Fiber Fabrication  
Microfluidics is a promising approach that uses small amount of materials for various 
applications such as biomedical areas and energy devices.29-35 This approach is the most recent 
of fiber fabrication methods applied to research in utilizing fibers as drug carriers.36  
In this method, fibers are fabricated by means of coaxial flow of pre-polymer (core fluid) and 
sheath fluid in a microchannel. Microfluidic fiber fabrication methods are particularly useful for 
drug delivery related applications due to the versatility, simplicity, and continuity of the process. 
There is no need for high electric currents, pressures, and temperatures, which improves the 
biological compatibility of the fiber fabrication process. Additionally, a variety of biocompatible 
and non-cytotoxic substances can be used in this approach. The size and shape of the fiber can be 
tuned by simply changing the parameters involved in the process as well as solidification 
strategy. Sub-methods of microfluidic fiber fabrication can be categorized based on the 
solidification strategy: photo-polymerization, chemical reaction, and phase inversion approaches. 
Photo-polymerization involves solidification of pre-polymeric molecules by means of free-
radical polymerization reaction within the microchannel. This method results in rapid and easy 
generation of solid fibers while maintaining size and shape.24, 37 In chemical reaction method, the 
bonding of pre-polymer molecules is facilitated by using small molecules or ions, such as Ca2+.24, 
38 In the phase inversion method, the solvent in the core stream of the microfluidic chip is rapidly 
removed by means of evaporation or extraction to expedite solidification of the polymeric 
fiber.24, 31, 32, 39 
 Each of these sub-methods have distinct advantages and disadvantages. In particular, 
photo-polymerization produces fibers in less than a second, and control over the fiber diameter 
over large spans of the fibers is significant. However, the degradability of the fibers fabricated by 
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photo-polymerization decreases, which could damage sensitive bacteria. Biodegradability and 
biocompatibility are the primary advantages of fibers fabricated using chemical cross-linking and 
phase inversion strategies. However, there are some limitations and difficulties associated with 
shape formation of the fibers due to the slower solidification rate of these two sub-methods.24  
Microfluidic fiber fabrication is a promising platform to fabricate fibers with a wide range of 
characteristics. However, the production rate in this technique is relative slow mainly because 
the flow has to be in the laminar regime. Otherwise, the fluids introduced in the microfluidic 
device, become mixed together and the diffusion will not occur only at the fluid/fluid interface. 
Moreover, the fluids, i.e. core and sheath fluids, has to be matched in terms of viscosity in order 
to keep the shear force at the fluid/fluid interface in the stable flow regime. In addition, there is 
always a possibility of the microchannel clogging due to undesirable shear force, which is 
originated from the mismatch between the properties of the fluids or inappropriate flow rate 
ratio. This issue can be minimized by adjusting the flow rate ratio between the fluids, 
concentration of polymer and cross-linking agent, and the UV intensity in a suitable range.31, 34, 40 
2.1 Magnetic-responsive and Photo-responsive Drug Delivery Systems  
Incorporating stimuli responsive properties to micro and nanofibers significantly increases the 
utility of such materials within biological environments.  Such stimuli responsive nanoparticles 
have been successfully used in drug/gene delivery,41 bio-separation,42 and magnetic resonance 
imaging,43 but rarely with micro and nanofibers. This is particularly true in drug delivery as the 
environment itself and the requirements for therapeutic material are constantly changing. These 
stimuli responsive characteristics, such as photo responsiveness,44 magnetic manipulation,45 and 
temperature sensitivity,46 are achieved by the incorporation of minute particles into the fiber 
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structure during the fabrication process. The advantages of fabricating such stimuli responsive 
therapeutic- incorporated materials and scaffolds are numerous. This work provides 
controllability, response properties, attenuation, and rapid drug release to micro and nanofibers. 
The advantages of such stimuli responsive fibers are ease of fabrication, high production rate, 
low cost, biocompatibility, and uniform distribution of magnetic particles in the fibers.47 
However, there are unique challenges associated with utilizing these fibers for actual drug 
release applications in vivo. One obvious practical difficulty would be implementing an optimum 
configuration of magnets when administering drugs using magnetic responsive fibers.48 Photo 
responsive drug loaded fibers are relatively easy to fabricate, but challenging to deploy as drug 
carriers. Nevertheless, once these challenges are overcome, stimuli responsive drug 
incorporating fibers have the potential to change the way that therapeutic substances are 
delivered to various cells and tissues in the body. 
The use of magnetite nanoparticles in hydrogel spheres for cell encapsulation related 
studies has been discussed as well. However, Lim et al. extended the method to microfibers.19 
The focus of the study was to incorporate stimuli responsive features to hydrogel microfibers 
fabricated by microfluidic approach with controllable size and morphology. As shown in Figure 
2 (a), a microcapillary device was used to generate Ca-alginate templates. In this process, 
hydrogel monomers were included and subjected to UV radiation (photo-polymerization) to 
create poly(N-isopropylacrylamide) (PNIPAm) based hydrogel microfibers. PNIPA was chosen 
for this study because of its temperature responsive nature. Furthermore, the resulting 
microfibers were photoresponsive due to the inclusion of photothermal magnetite nanoparticles. 
Ionic attractions were observed between the polymer and calcium ions facilitated by the capillary 
tubes and coaxial flows. This aided the uniformity and the small diameters required for the 
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templates. The microfiber diameter was controlled by adjusting the capillary tube sizes. Hollow 
fibers were obtained by changing the order of the inlets in microfiber fabrication. Functional 
materials were either blended into the core fluid or copolymerized. The response of PNIPAm 
microfibers, with blended in magnetite nanoparticles responsive to light and temperature, was 
observed in the form of volume change.  
The controllability of the microfiber could also be achieved by including magnetic 
nanoparticles in the alginate fiber fabricated with the microfluidic approach. Hu et al. obtained 
this result by evenly dispersing magnetic nanoparticles in alginate solution and subjecting it to a 
microfluidic fabrication process, illustrated in Figure 2 (b).49 This process was enhanced by 
incorporating hemicylindrical channels of multilayered pneumatic valves. The channels were 
capable of fully closing and regulating the flow rates of magnetic and non-magnetic alginate. 
Through this process, microfibers with different magnetic properties were produced. 
Importantly, there was no aggregation of magnetic nanoparticles produced by a precipitation 
method inside the alginate solution. This aided the uniformity of the final product during the 
fabrication process. The ability of the microfibers to be utilized in a magnetic field, to assist drug 
targeting, growth factor delivery, and possibly other kinds of therapeutics, makes it a candidate 
worthy of further investigation. This method could potentially address controllability, actuation, 
and response properties in drug delivery systems.  
Lin et al. also focused on the use of magnetic nanoparticles for fabricating stimuli 
responsive fibers for drug delivery. Their emphasis was laid on utilizing the unique stimuli 
responsive characteristics in drug release and cell encapsulation.45 As shown in Figure 2 (c), a 
microfluidic method that involved multiple inlets at different points along the center channel was 
utilized. In this design, alginate solution was controlled at different points along the channel in a 
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laminar flow regime. The diameter of the fibers was varied from 211 μm to 364 μm by changing 
the alginate solution flow rate. The magnetic iron oxide and diclofenac, the model drug, were 
incorporated into the alginate solution prior to the microfluidic fiber fabrication procedure. The 
drug release profile of the model drug demonstrated that the release process was linear, steady, 
and could be controlled externally by a magnetic field. This control is achieved by the attraction 
of the magnetic nanoparticles towards the magnetic field making the microfiber more porous. 
The initial burst rate observed in microfibers was smaller compared to spherical micro vesicles. 
Furthermore, the microfluidic method of microfiber fabrication results in a high encapsulation 
rate of 90% for both the magnetic iron oxide nanoparticles and the drug itself. Therefore, this is 
an efficient, convenient, and controllable method for drug delivery.  
 
 
Figure 2 Different fabrication methods of magnetic stimuli responsive micro and nanofibers: (a) 
Use of magnetite nanoparticles in hydrogel cell encapsulation. A mixture of sodium alginate, N-
iso-propylacrylamide (NIPAm), cross-linkers and photo-initiator in aqueous form was inserted at 
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inlet A. At inlet B, calcium ions were injected to diffuse into alginate and form calcium 
alginate.19 (b) The pneumatic micro valve structure used in microfiber fabrication.49 (c) 
Microfiber fiber fabrication system accompanied by photographs of the microfiber in the channel 
and two different junctions.45 
  
The magnetic responsive micro and nanofibers generated by the aforementioned means 
do not display morphological changes that might adversely affect their function in drug delivery. 
The cylindrical form of the fibers fabricated by Lim et al. are depicted in Figure 3 
(a) and (b).19  Figure 3 (c) and (d) show an alginate microfiber with diclofenac and magnetic 
iron oxide.45 Again the morphology is not significantly different from a regular alginate 
microfiber. These microfibers are shown in Figure 3 (e).49 
 
 
  
  
Figure 3 (a) EDTA treated poly(N-isopropylacrylamide) (PNIPAm) microfibers fabricated by 
microfluidic approach.19 (b) Optical micrograph of PNIPAm microfiber with an inner capillary 
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diameter of 500 µm.19 (c) Alginate microfiber for magnetic-responsive controlled drug release.45 
(d) SEM image of the fiber shown in part (c).45 (e) 100% alginate hydrogel microfibers 
fabricated by multilayered pneumatic micro valve based fabrication methodology. The horizontal 
scale bar represents 50 µm.49  
 
2.2 Other Innovative Approaches in Microfluidic-spun Fiber for Drug Delivery 
 Certain alterations have been introduced to this conventional microfluidic fiber fabrication 
procedure in order to ensure the enhanced functionality of fibers. These alterations include 
implementing a roller mechanism to draw out thinner fibers,50 composing fibers of triblock 
copolymers as opposed to conventional PLGA,51 and enhanced continuous production 
methods.36 In addition, attempts  have been made to use glass for making microfluidic chips, 
instead of PDMS, as glass has more desirable optical properties.52 Some research has been 
conducted on creating spherical vesicles from microfibers by drawing them out in a microfluidic 
arrangement. This method is unconventional in the sense that the fibers do not carry the drug to 
the target. In fact, they act as an intermediate stage in the final drug carrier fabrication.53 Some 
studies focus on increasing the concentration of loaded drugs, which may be essential in curbing 
rapidly spread infections.7 Each of these innovative approaches also have shortcomings, which 
shall be discussed on a case by case basis.  
 From a drug delivery system perspective, innovative methods for microfiber fabrication 
is important. Towards this end, Kang et al. described a solely PDMS based method of fabricating 
microfibers utilizing the cylindrical channel created by the deflection of a thin PDMS layer.54 
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The principle was extended for creating rectangular molds, and an additional 12 rectangular 
‘micromixers’ were created on a single chip with 5 coaxial flow channels. In these channels, 
microfibers with a different chemical composition were fabricated. The process and resulting 
fibers are schematically depicted in Figure 4. The diameters of the fibers fabricated were 75 μm 
to 115 μm. The core solution was Sodium Alginate and the sheath fluid was Calcium Chloride. 
Bovine Serum albumin (BSA) was successfully included in the fibers via the core fluid to 
demonstrate the ability of the fibers to carry therapeutic agents. However, the disadvantage to 
this method is the size limitation of the fibers, which could potentially be addressed by adjusting 
the flow rate and channel size of the coaxial flow. 
 
Figure 4 (a) Microfluidic fiber fabrication platform in which 5 fibers of different composition 
are fabricated in parallel. A stepwise gradient across 5 output solutions is achieved with 12 
rectangular micromixers and fibers were generated from these solutions through 5 coaxial flow 
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channels. (b) Illustration of the alligator teeth micromixer. (c) Coaxial flow channel with a single 
sheath inlet. (d) SEM image of alginate fiber.55 
 
Higher degree of control over fiber dimensions is important in creating fibers for drug 
delivery applications. Su et al. has investigated the possibility of using a roller assisted 
microfluidic system for generating alginate microfibers, where it is possible to exert such a 
degree of control.50 The alginate solution with the monomers and other particles, such as 
nanoparticles for drug delivery or cells for cell based therapy, were passed through a single 
microchannel. Then, calcium chloride solution was used to cross-link the alginate, which was 
collected with a roller, resulting in a microfiber. The roller was the critical component that 
reduced the diameter of the fiber to the order of 1 μm, and it also affected the shape of the fiber. 
Silver nanoparticles are important antimicrobial agents and possess wound healing properties. 
These particles were included by diffusing silver ions to the alginate microfiber and subjecting to 
UV light. Such nanoparticles could be potentially released in low concentrations to create 
antimicrobial activity in wound care applications. Biomaterials were included in the microfiber 
by blending with the alginate solution, which results in a successful method of incorporating 
anti-cancer drugs in drug delivery applications. This method could be applied to other hydrogel 
fiber types, which may increase the range of microfibers capable of incorporating drug delivery 
systems to their composition.  
In the field of Drug Delivery Systems, controlling the release rate of an encapsulated 
drug or a protein in the microfiber is an important factor. Marimuthu et al. successfully 
conducted a study where microfibrous scaffolds composed of amphiphilic triblock copolymer 
were fabricated utilizing microfluidics and the porosity was controlled.51 This controllable 
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porosity was obtained by combining the effects of immersion precipitation and solvent 
evaporation with the microfluidic generation of fibers. It was demonstrated that porosity of the 
fiber has a notable effect on release of Fibronectin, which was the model protein used. In 
principle, the method could be extended to use with gene therapy and other therapeutic agents in 
drug delivery systems. The copolymer used was an amphiphilic ABA copolymer (PPDO-co-
PCL-b-PEG-b-PPDO-co-PCL) capable of facilitating drug delivery due to its hydrophobic 
(PPDO/PCL) and hydrophilic (PEG) segments. Along with the enhanced drug encapsulation and 
release characteristics, the method is cost-effective, robust, and can be modified for other 
therapeutic applications.56 
As Berthier et al.  have pointed out, there are advantages specific to both polystyrene and 
PDMS as material for microfluidic apparatus as well as disadvantages.52 Of the two, polystyrene 
is more often used in conventional bio-related laboratory activities, but it has proven to be a 
difficult material to engineer. The same difficulties have been faced by researchers intending to 
use polystyrene in microfluidics, which has led to more prevalent use of other materials for 
research. Johnson et al. developed an innovative method to use PDMS molds to make 
polystyrene based microfluidic devices.57 Powdered Polystyrene in a petri dish was melted 
against a mold made out of PDMS to fabricate a microfluidic chip with channels and grooves. 
The absorption levels of drugs by devices fabricated were clearly demonstrated and compared to 
conventional PDMS devices. The results indicated that clopidogrel, the drug of choice for the 
study, is not absorbed by the PDMS material. Therefore, microfluidic devices could be used for 
laboratory drug delivery system related research, and in encapsulating drugs into microfibers. 
The required concentration of therapeutic substance has to be relatively high to have any 
effect on certain tissues or pathogens. Microfluidic fiber fabrication allows for creation of fibers 
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with a higher capacity to carry drugs. The deviation from the conventional method does not 
necessarily have to be structural, and it could be a change in the constituent materials used. Ahn 
et al. investigated a process in which certain details of the conventional microfluidic approach 
was changed in order to make the intended effect.7 Isopropyl alcohol was used as a sheath flow 
to create alginate polymer chains packed in a highly ordered and tight manner to form the fiber. 
This minimizes the swelling of the fibers and makes the concentration of the drug loaded in the 
fiber as high as possible. This overall arrangement of polymers within the fibers led to delayed 
degradation of the microfiber. The degradation was further slowed down by immersing the drug 
loaded fibers in a calcium ion bath. This was done to increase the cross linking of the polymers, 
which results in a stronger polymer. The core fluid was alginate solution with Ampicillin 
dissolved in it. Figure 5 (a) describes the fabrication of drug loaded alginate fibers with calcium 
chloride in deionized water as the sheath flow and in the coagulation bath. Figure 5 (b) depicts 
the fabrication procedure with calcium chloride dissolved in isopropyl alcohol as both the sheath 
fluid and the coagulation bath.  
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Figure 5 The schematic depicts the manner in which drugs are loaded into alginate fibers. The 
polymers aggregate and encapsulate the Ampicillin molecules along the direction of flow in each 
groove. (a) Fiber is fabricated with a solution of calcium chloride in deionized water as the 
sheath fluid; (b) Fiber is fabricated with a solution of calcium chloride in isopropyl alcohol (IPA) 
as the sheath fluid. In either case, the resulting fiber is passed onto a calcium chloride solution 
for further coagulation.7  
 
Ampicillin is a widely used antibiotic that is active against gram positive and gram 
negative bacteria.58 It was demonstrated that the drug loaded fibers were successful based on the 
antimicrobial action of drug loaded fibers placed in a bacterial culture. Further fibers were 
embedded in a chitosan patch and successfully used on a bacteria infected wound of a mouse. 
This experimental application is schematically depicted in Figure 6 (a). The actual structure of 
the dressing scaffold and the excision wound are shown in Figure 6 (b) and (c), respectively. 
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Figure 6 (a) Schematic of bacterial wound with fibrous scaffold containing drugs. The dressing 
scaffold is composed of alginate fibers with high concentration of ampicillin capable of exerting 
the necessary antibacterial action to control an infection. (b) SEM image of the actual dressing 
scaffold with the chitosan matrix and the ampicillin loaded fiber. (c) Excision wound.7 
 
The essential details pertaining to separate cases where micro and nanofibers fabricated 
by the microfluidic approach for drug delivery applications are given in Table 1. The core fluid, 
sheath fluid, diameter of the cross section, and the drug type (if indicated) used in each instance 
are indicated.  
 
Table 1 Details of fibers fabricated by microfluidic approach for drug delivery systems 
Authors Drug Type Diamete
r (µm) 
Core Sheath 
Lim et al.19 N/A  
10-600 
A mixture of Na-alginate, NIPAm,  
crosslinkers and photo-initiator in 
Ca2+ 
solution 
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aqueous form 
Hu et al.49 N/A  45-50 Alginate solution with magnetic 
nanoparticles 
CaCl2 
solution 
Lin et al.45 Diclofenac 211-364 Alginate solution and model drug CaCl2 
solution 
Mazzitelli et 
al.59 
Drug delivery 
systems CAM, 
ERSM, LS, 
and COBE 
180-500 Na-alginate through one inlet, Na-
alginate and drug delivery system ( 
CAM, ERSM, LS, or  COBE) 
through one inlet, Na-alginate and 
cell suspensions through one inlet. 
N/A 
Kang et al.55 BSA 75-115  Na- alginate solution and BSA CaCl2 
solution 
Su et al.50 Silver particles ~ 1  Na-alginate solution CaCl2 
solution 
Marimuthu 
et al.51 
Fibronectin 2 - 200  10% PPDO-co-PCL-b- 
PEG-b-PPDO-co-PCL copolymer 
in CH2Cl2 
DI water 
 Ahn et al.7 Ampicillin N/A Alginate and Ampicillin solution  CaCl2 in 
IPA or DI 
water  
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3. Electrospinning 
Electrospinning is a widely used and thoroughly investigated method of micro and nanofiber 
fabrication. In this method, the polymer is subjected to an electric field applied between a 
syringe containing the polymer and a collector. The jet moves in the air and during this time, it is 
either electrically deflected, collected on a grounded stationary metal screen,60 or on a grounded 
rotating or translating metal target.61 Different variants of this method exists, but the core 
concept is the same. By varying the conditions of the process, including the voltage and the 
material, fibers with a range of cross sectional diameters were obtained. The advantages of using 
electrospinning to fabricate macro and nanofibers in drug delivery systems include the ease of 
fabrication of fiber with diverse morphology and dimensions, the ability to include the 
therapeutic molecules into the polymer solution, and the ability to orient fibers either randomly 
or in an ordered manner, for tissue engineering related drug delivery applications.62  
Although electrospinning is a common approach for fabricating fibers, it has some disadvantages 
that adversely affect the biocompatibility aspect of this method. The diameter of the electrospun 
fibers is typically smaller than a single cell, which makes it challenging to encapsulate living 
cells and micro particles into the fibers.28, 63 Additionally, the common solvent that are used in 
this process, such as 2,2,2-Trifluoroethanol (TFE), tetrahydrofuran (THF), dimethylformamide 
(DMF), dichloromethane (DCM), chloroform, acrylic acid, and hexafluoroisopropanol (HFIP), 
have high toxicity.64 Due to the surface tension at the liquid/air interface, the cross-section of the 
electrospun fibers are mostly circular, whereas in microfluidic approach, the shape and surface of 
the fibers can be simply tuned by changing the 3D hydrodynamic focusing force.31, 34, 54, 65 
Beside the size and shape limitation and toxicity of the solvents,  the utilization of high electric 
fields (~1-2kV/cm) in this technique makes electrospinning unsuitable for certain drug delivery 
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systems where live cells need to be included in the fibers.28 However, due to the functionality of 
electrospinning method, many studies focused on improving the shortcomings exist in a typical 
electrospinning process.64, 66-68 For example, some reports showed that by simultaneously 
elesctrospinning fibers and electrospraying the cell suspension, the cells will have high 
viability.67, 68 There are some studies that drugs were encapsulated into the fibers, whereas in 
other reports, the combination of both fiber and liposomes were used to encapsulate the drugs 
and control its rate of release. 
3.1 Electrospinning fiber fabrication technique in drug delivery application 
Usage of micro and nanofibers in drug delivery is still an emerging topic in biomedical research. 
Due to the structural advantages fibers offer, they could be used in specific sites in the body in 
conjunction with tissue. The range of molecules that could be delivered by electrospun fibers 
extends from small biomolecules to molecules as big as proteins and DNA plasmids.69-75 Hence, 
this offers a significant advantage over conventional carriers.76 Additionally, subcellular vesicles 
and stimuli responsive time-variant morphological features could be incorporated into the fibers. 
However, further innovations could result in drug delivery systems designed for specific 
applications. Wound healing, for instance, is an area widely studied in applications of drug 
delivery systems which incorporate electrospun fiber structures. However, a single material may 
fall short in mechanical strength or may have less than optimal drug loading capacity in wound 
dressing applications. Bai et al. have succeeded in addressing both issues by fabricating a 
chitosan/polycaprolactone (CS/PCL) nonwoven mat utilizing the electrospinning method.77 The 
arrangement of fabricated fibers provide a greater area for active ingredients in the fiber to 
interact with the surroundings. Tree oil and calcium ions were incorporated into the chitosan 
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component of the structure, leading to increased platelet aggregation and antibacterial as well as 
anti-inflammatory effects, respectively.  
Releasing hydrophilic therapeutic compounds from hydrophobic fibers is a challenge. 
PCL-riboflavin nanofibers with radii ranging from 267±37 nm and gelatin-riboflavin microfibers 
with radii 2.18±0.3 µm were fabricated by Sridhar et al.78 Riboflavin is commonly known as 
Vitamin B2. It performs a range of critical metabolic functions as well as contributing to wound 
healing and maintaining tissue health.79, 80 Cross-linking was caused by the oxygen radicals 
generated by UV irradiation of riboflavin, which leads to an increase in mechanical strength of 
the fibers. This is schematically presented in Figure 7 (a). The Riboflavin release rate from these 
fibers was altered by treating the fibers with plasma and changing the plasma treatment duration. 
Therefore, non-cytotoxic riboflavin can function as a cross-linker and a therapeutic agent whose 
release rate can be controlled. Such riboflavin cross-linked fibers could be potentially used for 
fibrous scaffolds in tissue engineering applications such as dentin, parts of the eye, and the 
pericardium.  
 Oral ingestion of drugs is the most prevalent form of drug delivery in the pharmaceutical 
industry.81 Towards this end, Xu et al. created and investigated a drug delivery system consisting 
of Budesonide (BUD) loaded core/shell nanofibers that follows the aforementioned oral colonic 
pathway. Coaxial electrospinning was performed to prepare Budesonide loaded 
ethylcellulose(EC)-core/ Euragit S100-shell nanofibers, shown in Figure 7 (b). The diameter of 
these fibers averaged 190 nm and the average core diameter, which is uniform throughout the 
length, was 74 nm. Budesonide-loaded Eudragit S100/ ethylcellulose nanofibers, which are 
regarded as composite nanofibers, were fabricated utilizing blend electrospinning. The composite 
fiber was used as a control and both were subjected to in vitro and in vivo tests, the latter being 
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carried out in rats. It was observed that the desired pH dependent behavior was observed from 
the Budesonide loaded core/shell nanofibers, and the encapsulated drug was shielded from the 
acidic contents of the stomach and small intestine until the colon was reached. Budesonide in 
nanofiber encapsulated form could potentially be used for future application in an oral colonic 
drug delivery system. This is a possibility due to the advantages this particular method offers 
over the current conventional method used in the pharmaceutical industry. 
Rubert et al. investigated fibroblast growth factor delivery and tissue engineering 
applications of PEO/PCL electrospun coaxial microfibers.82 Fibrous cartilage in the human body 
heals at a slower rate due to the lack of cells which produces collagen. Figure 7 (c) shows a 
method in which PCL/PEO coaxial microfibers were loaded with fibroblast growth factor. The 
fibers had an outer surface made of PCL and the fiber diameters ranged from 7.49±0.835 µm to 
7.489±0.445 µm. As noted in previous reviewed work, electrospinning parameters could be 
adjusted to change the fiber morphology to the desired form. The therapeutic substance was 
encapsulated properly, and the release lasted over 9 days. It was observed that the growth factor 
was expressed more after the first day, but reduced in release after day 9, proving that the 
method could be a potent form of growth factor delivery based on microfibers. Lei et al. utilized 
electrospun PLGA microfibers to deliver designer RNAi plasmid, complexed with a gene carrier 
polyethylenimine, to treat brain tumor by suppressing the expression of Matrix 
metalloproteinase-2 in tumor cells.83 Anticancer drug paclitaxel and the RNAi plasmid were dual 
encapsulated in disc shaped implants composed of electrospun PLGA microfibers. The 
microfiber implant was able to release the drug and the gene in a sustainable manner. The 
gene/drug delivery was observed to be capable of greater tumor regression compared to the 
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single delivery of a drug by a microfiber or commercial drug treatment currently available. The 
microfibers that constitute the disc shaped implant had diameters of 835±92 nm.  
Pre-exposure prophylaxis of HIV is an important step in preventing the spread of the HIV 
virus. Implementing such methods in a precoital vaginal settings have unique challenges. 
Rapidly releasing a large volume of the drug without discomfort is difficult to accomplish with 
conventional drug delivery systems. Ball and Woodrow fabricated PVP and PEO microfibers 
loaded with maraviroc shown in Figure 7 (d). Maraviroc is the prophylactic drug, while 
polysorbate 20 is the wetting agent which aids quick release of the drug.84 The fibers ranged in 
diameter from 0.4 to 2 µm. The drug loading was up to 28% wt and conditions of high moisture 
were facilitated to result in rapid release of the whole 28% wt of the drug under 6 minutes under 
sink conditions. During the electrospinning process, the drug retained the original potency and 
had no side effects. This could form the basis of a novel prophylactic measure to curb the 
spreading of HIV due to the efficiency of the drug release mechanism. 
 
 
Figure 7 (a) Schematic depicting the cross-linking of gelatin nanofibers with riboflavin which 
may potentially be used in the dentin, pericardium or the eye.78 (b) BUD-core/shell-nanofibers 
(a) 
(d) 
(b) 
(c) 
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that could be potentially used for drug delivery.81 (c) PVP and PEO fibers containing HIV 
prophylactic drug Maraviroc.84 (d) Coaxial PCL/PEO hollow fibers which may be loaded with 
dexamethasone for inflammation treatment.82 
3.2 Drug delivery in Conjunction with Liposomes and Electrospun Micro and Nanofibers 
Liposomes are spherical subcellular vesicles with at least a single lipid bilayer, and have been 
extensively used for experimental and clinical studies in drug delivery.85 The ability to load the 
vesicle with various molecules ranging from chlorine in wool chlorination86, 87 to 
chemotherapeutic nanomedicines to treat cancer e.g. Camptothecin and platinum (II) drugs,88 has 
made liposomes an ideal nanocarrier, particularly in drug delivery. 
The reasons for the popularity of liposomes, for drug delivery, include the longevity of 
liposomes in the bloodstream, ability to penetrate cells in the delivery of substances, and the 
stimuli sensitive nature of liposomes. In research carried out by Mickova et al. horse radish 
peroxidase was used as the model encapsulate, and its enzymatic activity was preserved. This 
lead to the conclusion that the mesenchymal stem cell proliferation was enhanced by the delivery 
of recombinant growth factors provided by this drug delivery system.89 In addition, there is 
potential for clinical applications based on the use of stimuli responsive liposomes in drug 
delivery. 90 Liposomes, which are adherent to microfibers, are capable of encapsulating a range 
of important biomaterials ranging from drugs to DNA. Here, we have a closer look at the various 
fabrication methods in which liposomes have been incorporated to fibers. 
Liposomes, blended with polyvinyl alcohol-core/poly-ε-caprolactone-shell nanofibers, 
were fabricated by coaxial electrospinning as well as controls with no embedded liposomes.89 
According to stereological measurements, the controls had nanofiber populations with peak 
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diameters of 50 nm and 150 nm, while the liposome embedded fibers had bulges along the length 
with diameters 233.4±36.9 nm with embedded liposomes at places. The appearance of such 
liposome embedded fibers is shown in Figure 8.  
 
 
Figure 8 (a) FESEM image of coaxially electrospun PVA-core/PCL-shell nanofibers with 
liposomes encapsulated along the length of the fiber. (b) The bulge caused along the length of 
the nanofiber due to the liposome is clearly seen.89  
 
Incorporation of magnetic nanoparticles is a common way of introducing stimuli 
responsive properties to drug delivery systems.91, 92 This is applicable to liposomes as well. For 
example, fibers were electrospun from a core solution containing polyvinylpyrrolidone K90, 
phosphatidyl choline, and Fe3O4 nanoparticles, then subsequently added to water.90 It was 
observed that the fibers have the Fe3O4 particles uniformly distributed. This process is illustrated 
in Figure 9 (a). The fibers were observed to spontaneously undergo self-assembly to form 
liposomes. Additionally, the size was seen to vary with the Fe3O4 concentration. The retention of 
sensitivity to magnetic stimuli was observed to be retained throughout the electrospinning and 
self-assembly processes. An actual view of the liposomes obtained is shown in Figure 9 (b). 
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Similar but non-stimuli responsive liposomes were fabricated through molecular self-assembly 
by adding electrospun amphiphilic nanofibers composed of hydrophilic polymer 
polyvinylpyrrolidone K60 (PVP) and soybean lecithin.93 The liposomes were phosphatidyl 
choline (PC) and diameter was varied by changing the PC content of the fibers.  
 
 
Figure 9 (a) Schematic of magnetic liposome self-assembly. Fe3O4 nanoparticles are stirred into 
the polymer solution, then subjected to electrospinning fabrication process. Once hydrated, 
liposomes form through self-assembly. (b) SEM micrograph of a magnetic liposome fabricated 
from the fibers by self-assembly process, which results in stimuli responsiveness in addition to 
drug delivery capacity.90  
 
Rampichova et al. utilized the process of microfiber fabrication by electrospinning to 
produce poly(2-hydroxyethyl methacrylate) (PHEMA) fibers to be used as a tissue engineering 
scaffold for cartilage. The fibers fabricated had diameters in the submicron range.94 In addition, a 
relatively straightforward drug delivery system was created in which fetal bovine serum loaded 
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liposomes were anchored to the fabricated fibers. This anchoring occurs as a result of the 
adhesion of liposomes to PHEMA. An enhanced proliferation of chondrocytes, in the vicinity of 
such liposomes attached to the fibers, was found. This observation showed the development of 
controlled drug release mechanisms in conjunction with microfibers in tissue engineering 
applications.  
3.3 Miscellaneous Innovations in Electrospun Fiber Based Drug Delivery 
Programmable Transdermal drug delivery is one such exploratory application of micro and 
nanofibers in drug delivery systems. Tran et al. incorporated two types of ibuprofen (an anti-
inflammatory drug) into the microfibers using an electrospinning approach.95 One type of 
microfibers were fabricated from polycaprolactone (PCL), while the other type was composed of  
poly(N-isopropylacrylamide-co-methacrylic acid) (pNIPAM-co-MAA). The average diameter of 
PCL fibers was 1237 nm, whereas that of pNIPAM-co-MAA fibers was 1608 nm. The drug 
release characteristics under different pH and temperature conditions, from both types of fibers, 
was investigated. It was revealed that the drug release rate from PCL fibers is largely 
unresponsive to both pH and temperature changes whereas pNIPAM-co-MAA drug release rates 
were highly sensitive to changes in the above mentioned conditions. The drug release profile 
from the latter was linear and controllable at temperatures higher than the lower critical 
temperature of pNIPAM-co-MAA and at a pH higher than the pKa of carboxylic acids. 
Furthermore, at room temperature, the drug release rate from pNIPAM-co-MAA was shown to 
be ten times higher than the release rate at a higher temperature. Therefore, the highly stimuli 
responsive nature of ibuprofen loaded pNIPAM-co-MAA fibers can be utilized in future in vivo 
and potentially clinical applications. 
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A nanofiber based drug delivery system, capable of exercising precise control over drug 
delivery, by means of coating with nanotubes, has been investigated by Abidian et al.96 
Biodegradable drug loaded poly (L-lactide) (PLLA) and poly(lactide-co-glycolide) PLGA 
nanofibers with diameters ranging from 40-500 nm were fabricated by electrospinning. The drug 
loaded into the fibers in the study was dexamethasone. The nanofibers were coated with 
poly(3,4-ethylenedioxythiophene) (PEDOT) nanotubes by means of electrodeposition. The 
process is detailed in Figure 10. This conducting nanopolymer coating significantly reduces the 
impedance and increases the charge capacity such that drug release from the fibers can be 
simulated to a desired extent, by means of electricity. Due to the controllability and precision of 
the mechanism, this can be a potential drug delivery system. 
  
 
Figure 10 Schematic diagram of controlled release of dexamethasone. (a) Electrospun PLGA 
fiber loaded with dexamethasone. (b) Degradation of PLGA fibers by hydrolysis, which results 
in releasing the drug. (c) Electrochemical deposition of PEDOT around the PLGA fiber. (d) This 
results in the sustained release of the drug over time. (e) PEDOT nanotubes in a neutral electrical 
condition. (f) Applying a non-zero voltage allows to exert control over rate of dexamethasone 
release due to contraction or expansion of the PEDOT. (g) A PEDOT nanotube which was 
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formed around a PLGA fiber. The PLGA solution of fiber was subsequently dissolved resulting 
in this appearance.96 
 
Zhou et al. devised a method to exert more control over drug release by fabricating water 
soluble drug loaded ultra-fine fibers by means of microsol-electrospinning.97 Core-shell poly(L-
lactic acid) microfibers loaded with chloroquine-hyaluronic acid nanoparticles were created by 
microsol electrospinning. Chloroquine phosphate, which is the therapeutic substance used in the 
study, is historically noted for being used in the treatment of falciparum malaria, vivax 
malaria,98, 99 infections caused by protozoa,100 and certain other diseases. The fabricated fibers 
had diameters ranging from 1.33±0.32 µm to 1.48±0.44 µm and cores ranging from 0.29 to 0.83 
µm depending on composition of hyaluronic acid and drug constituent ratio in the fibers. The 
morphology and physical features of such fibers were no different than fibers fabricated from 
conventional electrospinning. The loading efficiency of the microfibrous scaffolds was 
approximately 80%. The burst release was lower than conventionally prepared microfibers, and 
drug release occurred for 42 days. The rate of drug release could be adjusted by changing the 
concentrations of microsol and drug in the fibers. 
Puhl et al. fabricated non-woven PCL microfibers with diameters ranging from 1.6 to 10 
μm by electrospinning, and lysozyme crystals with diameters in the range of 0.7-2.1 µm were 
encapsulated during the process.101 Lysozyme, an enzyme in the crystalline form, is the most 
concentrated form of the protein which makes for increased drug loading.102 The enzyme itself is 
used for wound treatment, and electrospun chitosan mats, which are loaded with it, have been 
used for wound healing.103 In the study, the fiber diameter and the lysozyme loading 
concentration were varied. Additionally, PCL/PEG and PCL/PLGA blends were used to enhance 
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the hydrophilic nature, porosity, and degradability of the fibers, which in turn affects the drug 
release profile. It was observed that the bioactivity of the encapsulant was preserved during the 
electrospinning, and the burst release could be controlled by changing the aforementioned fiber 
and crystal properties. These factors did not affect the long term drug release phase, but it was 
extended to over 11 weeks by PLGA inclusion during the electrospinning fabrication.  
Llorens et al. obtained a method in which both antimicrobial and anticancer drugs were 
released from the same scaffold composed of microfibers fabricated using electrospinning.104 In 
this study, uniaxial microfibers were fabricated by varying core-shell compositions and 
distributions. This was accomplished by subjecting ploy(ethylene glycol) (PEG) and 
poly(butylene succinate) (PBS) in a dichloromethane solution to coaxial electrospinning. The 
diameters of the core/shell fibers ranged from 4.40±0.92 µm to 4.83±1.27 µm, and for the 
uniaxial blended fibers were in the range of 0.43±0.10 µm - 0.76±0.18 µm. The core-shell 
microfibers were prepared such that the hydophobic drugs triclosan and curcumin were loaded 
into PEG and PBS, respectively. The triclosan incorporated into PEG lead to the rapid release 
often needed to combat microbial infections. Moreover, a slower sustained release required for 
anticancer therapy was displayed by curcumin loaded in PBS.104 The drug loaded fibers were 
observed to be biocompatible upon investigation, and the release profiles of drugs in different 
media were compared. It was observed that lowest release rate was found in PEG-rich uniaxial 
fibers in a buffer saline medium, whereas highest release was obtained in coaxial microfibers in 
buffer saline/ethanol mixture.  
Fibers have also been electrospun from biological molecules. A prime example is the 
fabrication of Hemoglobin and Myoglobin mats by means of electrospinning approach 105. The 
fibers produced in this manner were ribbon-like. The dimensions varied with the concentration of 
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hemoglobin and myoglobin in the electrospun solution. For hemoglobin concentrations from 150 
to 225 mg/L, the average width and thickness of fiber mats changed from 2.68 ± 0.83 μm to 3.55 
± 1.49 μm and from 0.49 ± 0.08 μm to 0.99 ± 0.41 μm, respectively. It was found that there is a 
correlation between porosity of the fibers and the hemoglobin concentration. These fibrous 
structures could function as vehicles for drug delivery.  
3.4 Controlled Drug Release with Electrospun Micro and Nanofibers 
Drug release profiles of micro and nanofiber based drug delivery systems are an important 
factor. For example, acute microbial infection control requires the release of a large dosage of 
drug in a specific location over a short period of time. However, treatment of a chronic infection 
or containing the spread of a tumor requires a longer sustained release of the drug in controlled 
quantities.106 Typical release profile of a drug delivery system consists of a rapid initial burst 
release followed by a longer period of controlled release.16 This is shown in schematic form in 
Figure 11 (a).  The drug has to be administered less frequently to the patient because of the 
sustained release of the drug.107 This sustained release resembles the flat portion of the separate 
plots depicted in Figure 11 (b).108 The release rates and the time at which the release rate 
plateaus out depends on the drug molecule, concentration of the drug molecule in the fiber, and 
the nature of the fiber itself.69-72, 74 Luu et al. incorporated DNA into a fibrous scaffold made by 
PLGA and PLA-PEG block copolymers. They showed that the DNA release can be controlled by 
changing the block copolymer content.69 Another example is a study by Qi et al. in which drug-
fiber combinations drastically affect the burst and sustained release profiles for drug molecules is 
shown in Figure 11 (c).109 The effect of drug concentration on the release profile is clearly 
 33 
 
observed in Figure 11 (d).10 These can be attained on a case by case basis just by adjusting the 
varying burst release properties of the encapsulated drug or the sustained release. 
  
Figure 11. A general overview of drug release profiles. (a) A schematic depicting the manner in 
which burst-effect in a zero order controlled drug delivery.16 (b) The release profiles of protein 
and dye in DMSO (Dimethyl Sulfoxide) and dichloromethane from microfluidically fabricated 
fibers.108 (c) The release profiles of tetracycline hydrochloride (TCH) from electrospun  TH-
1/PLGA, TH-2/PLGA, tetracycline hydrochloride loaded /poly(lactic-co-glycolic acid) 
composite nanofibers (TCH/PLGA) nanofibers, and tetracycline hydrochloride loaded halloysite 
nanotubes (TCH/HNT) fibers.109 (d) Release profiles of chlorhexidine (CHX) in 
poly(hydroxybutyrate) (PHB) and poly(hydroxybutyrate)/poly(ethylene oxide) (PHB/PEO)  
electrospun fibers.10 
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When conventional methods of drug loading are followed with electrospun fibers, burst 
release effect, observed at the outset, hampers the effectivity of the blended or mixed drug. This 
is a major disadvantage in drug delivery system applications. Qi et al. addressed this issue by 
fabricating tetracycline hydrochloride (TCH) loaded halloysite nanotubes (HNTs)/poly(lactic-co-
glycolic acid) composite nanofibers (TCH/HNTs/PLGA) with improved tensile strength, 
sustained 3D form, and cytocompatibility.109 TCH, the pharmaceutical substance applied in the 
study, is an antibiotic which is extensively used to treat periodontal infections 110, 111 and 
periodontal applications in veterinary medical applications.112 Additionally, the composite fibers 
had the ability to overcome the initial burst release effect and release the antibiotic drug in a 
sustained manner for 42 days. Hence, the intended TCH induced therapeutic effect is sustained 
and lasts longer. The fabrication process involved TCH encapsulation within HNTs, and the 
composite fibers were electrospun from the solution with PLGA. The diameter of fabricated drug 
loaded composite fibers was 519 ± 133 nm.  
Li et al. took a similar comparative approach to study the effects of binary fibers which 
were loaded with Dexamethasone in anti-inflammatory applications.113 Dexamethasone is a 
synthetic glucocorticoid, which is used primarily as an anti-inflammatory drug in a clinical 
context,114 however, it may also be used for unconventional applications such as treatment of 
bacterial meningitis 115 and multiple myeloma.116 Immiscible polymer blends of 
polycaprolactone (PCL) and polyethylene oxide (PEO) were prepared with different 
compositions of the two constituents in each case. The general physical characteristics of the 
fibers were not changed in the direct loading of the drug during the electrospinning process. 
Depending on the relative composition of each component, the physical structure of the fibers 
varied from straight, straight with pores, to porous lamellar. The diameter of the fibers ranged 
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from 0.92 ± 0.61 μm to 4.782 ± 0.37 μm. The nature of Dexamethasone release was a function of 
the wettability of the fiber, with highly hydrophilic compositions leading to minimize the 
undesired burst release. Regardless of the morphology and other chemical properties, all fibers 
were biocompatible. The dexamethasone was effective in reducing inflammation caused by 
Lipopolysaccharides.113 
Inclusion of other nanostructures in microfibers generated by electrospinning could assist 
in a desirable drug release profile. In a study, drug-loaded halloysite clay nanotubes, with 50 nm 
diameter and length of 600 nm, were embedded into Electrospun PCL/gelatin microfibers with 
mean diameter of 400 nm.117 Prepared halloysite loaded microfibers were formed into a 
membrane with tensile strength doubling in the direction of the rotation of the collector. The 
embedding of drug loaded halloysite nanotubes into the fibers resulted in a drug release period of 
over 20 days compared to the control, in which the drug was directly loaded to the PCL/gelatin 
fiber which lasted for a mere 96 hours.109 This microfiber-halloysite membranous structure had 
good biocompatibility and eukaryotic cells were able to grow along the membrane. Furthermore, 
the drug acted to prevent the colonization of anaerobic Fusobacteria. 
The same principle of including nanostructures in the micro and nanofiber structure has 
been explored by Valarezo et al. by including layered double hydroxide (LDH) nanoparticles 
within electrospun PCL microfibers.118 The drug Amoxicillin was interspersed within the 
nanostructures. The interspersion of the drug in LDH was done by a co-precipitation process. 
These PCL fibers were organized into non-woven mats with individual fibers of an average 
diameter of 0.8 μm. The fibers were randomly oriented in these structures, and the drug loading 
along with the nanoparticles appeared to slightly increase the average cross sectional area of the 
fibers. The initial burst release, followed by sustained release of the drug, was observed in this 
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case as well. However, the intercalation of the drug within the LDH allowed for a slower 
sustained release. There is potential for successful use of this method for wound dressings, oral 
care, and dermatological treatment applications. Rubert et al. fabricated coaxial electrospun 
fibers with the same constituents in which dexamethasone was encapsulated.82 The fibers were 
hollow fibers of the core-shell type with a highly porous morphology conducive to drug release. 
The diameter of the fibers was 8.255 ± 0.838 μm and 8.7± 0.813 μm before and after 
dexamethasone encapsulation, respectively. The release of the drug occurs in two stages; the 
burst release occurs in the first 0.5-3 hours, and a late more stable release over more than 12 
days. This dual stage drug release property makes this drug loaded electrospun microfiber 
structure ideal for implantation and acute inflammation as well as for chronic inflammation 
control. The drug loaded fibers were successful in reducing the proliferation of 
lipopolysaccharide (LPS) stimulated macrophages and at expressing inflammation related genes. 
Paclitaxel is an anti-tumor drug that acts to inhibit tumor cell growth by enhancing 
microtubule assembly resulting in blocking cell replication.119 This drug has been widely used in 
clinical anti-cancer applications. Huang et al. successfully fabricated paclitaxel loaded poly(L-
lactic acid-co-ε-caprolactone) (P(LLA-CL)) microfibers utilizing coaxial electrospinning.120 The 
diameters of the fibers were 233± 68 nm for fibers with 4% P(LLA-CL) by weight and 
1459±150 nm for 10% P(LLA-CL). The solvent used in electrospinning was 2,2,2- 
trifluoroethane (TFE). As in previous cases, there was burst release initially for the first 24 hours, 
then sustained release for the next 60 days. The drug release involved polymer degradation and 
diffusion, however this rate depended heavily on the concentration of initial drug loading. The 
accumulation release of the drug and the release rate are inversely related to the length of the 
hydrophobic polymeric chain and drug loaded concentration. The cytotoxic nature of the drug 
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loaded fibers successfully inhibited HeLa cell growth indicating the potential success of the 
method for anticancer drugs and other therapeutic substances with a hydrophobic nature.  
Sabitha and Rajiv applied a different approach to include drugs into electrospun fibers by 
facilitating imbibition of tigecycline in PCL urethane urea microfibers.121 This was performed by 
immersing the fibers in a tigecycline solution. The diameter of the fibers was 1.5-2 µm after drug 
imbibition has taken place. The imbibition of the antibiotic improved the thermal stability of the 
fiber. In addition, typical initial burst release followed by sustained release over a prolonged 
period of the drug was observed. The antibiotic activity was retained after the fabrication 
process. This method could potentially be utilized to create a scaffold to manage soft tissue 
infections and as a bandage to prevent such infections. 
Although a survey of literature relevant to micro and nanofiber fabrication reveals the 
widespread use of certain materials for micro and nanofiber fabrication, such as alginate and 
gelatin, other materials could be used such as animal proteins. For example, micro and 
nanofibers from cod (Gadus morhua) sarcoplasmic proteins were electrospun by Stephansen et 
al. to investigate the bioactivity, ability to encapsulate drugs, and the nature of drug release from 
drug incorporated fibers.122 The fiber diameter was dependent on the cod sarcoplasmic protein 
concentration of the electrospun solution with fiber diameters ranging from 100 nm for lower 
concentrations to 1000 nm and higher for higher concentrations. The water insoluble fibers were 
hydrolyzed by proteinases to result in small peptides which were the immediate product that 
successfully inhibited diabetes related enzyme DPP-IV demonstrating its bioactive property. 
Dipeptide Ala-Trp encapsulated in the fibers was used to study the drug release profile from the 
fiber in both gastric and intestinal buffer. The drug release profile was different in this case 
where the burst release phase took place within 1 minute, resulting in release of 40% of the 
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encapsulated substance, the next 30% within 30 minutes (gastric buffer), and 15 minutes 
(intestinal buffer) for gastric and intestinal buffer respectively.  The last 30% is assumed to be 
released in a sustained long term manner as it was not released within the duration of the 
experiment. The encapsulation of Rhodamine B was done to study the manner in which 
encapsulated compounds are distributed. This demonstrated that the distribution is largely 
uniform, except for certain regions, possibly due to the high density of the protein fiber network. 
The study demonstrates the potential use of the cod sarcoplasmic fibers for encapsulating and 
carrying bioactive peptides for therapeutic purposes. 
The clinical applications of matrices composed of electrospun nanofibers are numerous. 
In this regard, biodegradable polydioxanone (PDS II®) periodontal drug delivery systems, 
incorporated with either metronidazole (MET) or ciprofloxacin (CIP), have been electrospun. 
They were used to investigate the effects of antibiotics on oral commensal bacteria as well as 
pathogenic bacterial species.123 The fibers were electrospun from PDS solutions containing 5 
wt.% MET, 25 wt.% MET, 5 wt.% CIP, and 25 wt.% CIP. In this study, pure PDS fibers were 
fabricated as a control. It was noticed that while the highest fiber diameters were observed in 
pure PDS fibers at 1,158 ± 402 nm, the lowest diameters were observed in 25 wt% CIP 
incorporated fibers. Furthermore, fibers with higher weight percentage of incorporated 
therapeutic molecules released drugs for longer than others. As desired, CIP fiber matrices 
significantly inhibited periodontopathogens without inhibiting the activity of commensal oral 
bacteria. Thus, it was recommended to do in vivo tests using animal models in order to test the 
viability of this method for clinical applications.  
Additional research has been done on utilizing electrospun fibers for oral drug delivery 
applications.124 A triple antibiotic paste-mimic scaffold was fabricated by adding Metronidazole, 
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ciprofloxacin, and Minocycline to a Polydioxanone (PDS) solution then subjecting it to 
electrospun fibers. The diameter of the pure PDS scaffold was 689 ± 312nm, whereas that of the 
TAP mimic was 718 ± 125 nm. The purpose of the study was to study the effectiveness of the 
TAP-mimic scaffold for drug delivery to Actinomyces naeslundii, often seen in traumatized 
permanent teeth diagnosed with necrotic pulps. Towards this end, a rapid burst release was seen 
in the first 24 hours of application, whereas a slow sustained release was observed for the 
following four weeks of both drugs save for minocycline. Compared to the negative control, 
which consisted of a 7-day old biofilm infected dentine and pure PDS scaffolds, the TAP-mimic 
scaffold was successful in reducing viable bacterial populations. The sustained drug release and 
the cytocompatibility of metronidazole(MNA)- loaded electrospun fiber mats made them 
significant candidates for clinical applications, particularly in the treatment of periodontal 
diseases. In research conducted by Reise et al., polylactide (PLA) fibers integrated with 0.1-40% 
(w/w) MNA were electrospun and the release profiles of MNA from these fibers were 
investigated.125 The diameters of the fibers fabricated ranged from 0.64 to 1.2 µm. MNA yielded 
fibers with the smallest diameter and the highest surface area to volume ratio resulting in the 
highest initial release rate. This rate decreased over time until the third day then followed a linear 
trend beyond that period. Furthermore, 32-48% of the drug was released in the first week and 
release of MNA lasted till the end of 4 weeks. It was observed that mats with 48% MNA resulted 
in effective action against F. nucleatum and P. gingivalis. Additionally, Rho et al. utilized 
electrospun collagen nanofibers for early stage wound healing and interaction with human 
keratinocytes.126 Type I collagen in 1,1,1,3,3,3-hexafluoro-2-propanol were embedded into 
electrospun fibers and the diameter ranged from 100 nm to 1200 nm. These nanofibers form a 
matrix that was crosslinked by glutaraldehyde vapor with a saturated aqueous solution. The 
 40 
 
cross-linked matrix was then treated with 0.1 M glycine. The tensile strength and high 
cytocompatibility make these structures ideal for tissue engineering scaffolds. Furthermore, the 
interactions of keratinocytes and the nanofibers that constitute the matrix allow early stage 
wound healing. 
The material composition of the electrospun fiber, drug used, target organ or tissue and 
the diameter of each of the cases discussed in this section are detailed in Table 2. 
 
Table 2 Details of fibers fabricated by electrospinning for drug delivery systems 
Author Material Drug Function Diameter 
Rampichov
a et al.94 
PHEMA BSA Chondrocyte seeding 
and proliferation 
2.1±0.6 µm to 3.6±1.3 µm 
Bai et al.77 CS/PCL tree oil, 
calcium ion 
Wound healing 2.51±0.69 μm 
Qi et al.109 TCH/HNTs
/PLGA 
TCH Antibacterial action 519±133 nm 
Li et al.113 PCL and 
PEO 
Dexamethaso
ne 
 
Anti-inflammatory 
action 
0.92±0.61 μm to 4.782±0.37 
μm  
Rubert et 
al.82 
PCL and 
PEO  
Dexamethaso
ne 
Anti-inflammatory 
action 
8.255±0.838 μm and 
8.7±0.813 μm  
Valarezo et 
al.118  
PCL Amoxicillin Wound dressings, 
oral care and 
0.8 μm 
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dermatological 
treatment 
applications 
Huang et 
al.120 
P(LLA-CL) Paclitaxel  Anticancer 
therapeutic 
233±68 nm 1459±150 nm 
Sabitha 
and 
Rajiv121 
PCL 
urethane 
urea 
Tigecycline  Soft tissue infections 
and as a bandage  
1.5-2 µm 
Stephansen 
et al.122  
 Cod 
sarcoplasmi
c protein  
Dipeptide 
Ala-Trp  
Bioactive peptides 
for therapeutic 
purposes 
100-1000 nm 
Bottino et 
al.123 
polydioxan
one 
Metronidazol
e, 
ciproflaxin 
Inhibiting 
peridontopathogenic 
activity 
765± 288nm to 1158± 402 
nm 
Albuquerq
ue et al.124 
polydioxan
one 
Metronidazol
e, 
ciprofloxacin
, 
Minocycline 
Inhibiting 
actinomyces 
naeslundii activity 
689 ± 312 nm to 718 ± 125 
nm 
Reise et 
al.125 
polylactide metronidazol
e 
Peridontal disease 
treatment  
0.64 to 1.2 µm 
Rho et 
al.126 
type I 
collagen 
 Early stage wound 
healing 
100–1200 nm 
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Xu et al.81  EC/ 
Eudragit 
S100 
Budesonide Drug dependent 74 nm-core 
190 nm- shell 
Llorens et 
al.104 
PEG and 
PBS) 
Triclosan  
Curcurmin 
Treatment of 
microbial infection 
and 
cancer 
core/shell- 4.40±0.92 µm to 
4.83±1.27 µm  
uniaxial blended fibers-
0.43±0.10- 0.76±0.18 µm 
Tran et 
al.95  
PCL/ 
pNIPAM-
co-MAA 
 Ibuprofen  Anti-inflammatory 
drug action 
pNIPAM-co-MAA fibers 
were 1608 nm, PCL was 1237 
nm 
Abidian et 
al. 96 
PLLA/ 
PGLA, 
coated with 
PEDOT 
nanotubes 
Dexamethaso
ne 
Antibiotic/ 
antifungal action 
40-500 nm 
Mickova et 
al.89 
PVA/ PCL Horseradish 
peroxidase/ 
growth factor 
Mesenchymal stem 
cell proliferation 
50 nm and 150 nm, peak 
diameters of 50 nm and 150 
nm 
Zhou et 
al.97 
Core-shell 
PLLA 
microfibers 
Chloroquine Treatment of 
Malaria  
core:1.33±0.32 µm to 
1.48±0.44 µm 
shell: 0.29-0.83 µm 
Puhl et 
al.101 
PCL Lysozyme Wound dressing 1.6-10 μm  
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Sridhar et 
al. 78 
PCL/ 
Gelatin 
Riboflavin Therapeutic action 1.7-2.2 μm 
Rubert et 
al.82 
PEO/PCL  Fibroblast 
growth factor  
Cartilage 
`regeneration 
7.49±0.835 µm to 
7.489±0.445 µm 
Ball and 
Woodrow 
84  
PEO/ PVP Maraviroc HIV prophylaxis 400-2000 nm 
Xue et 
al.117 
PCL/gelati
ne 
Metronidazol
e 
Antimicrobial action 400 nm 
Lei et al.83 PLGA RNAi 
plasmid 
Brain tumor therapy 
(Matrix 
metalloproteinase-2) 
835±92 nm 
Barnes et 
al.105 
Hemoglobi
n and 
Myoglobin 
Could 
Potentially 
be used 
Could Potentially be 
used 
Width and thickness: 
2.68 ± 0.83 to 
3.55 ± 1.49 μm and from 0.49 
± 0.08 to 0.99 ± 0.41 μm 
 
4. Wet spinning, Rotary spinning, and Molding Approaches in Drug Delivery  
Wet spinning and rotary spinning have been used less often in fabricating fibers for drug delivery 
related research, but they are among the older methods used in fabricating fibers. In wet 
spinning, the biomaterial is dissolved in deionized water and stirred at high angular velocities to 
generate a viscous solution. The solution is then extruded into a coagulation bath and dried to 
obtain the fiber for the desired application.127-130 Although this method is simple, there is 
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potential for long term exposure of cells to cytotoxic chemicals used during the fabrication 
process.28 As a result, fibers used in drug delivery applications, with cell encapsulation involved, 
may not be fabricated by wet spinning. In rotary spinning, high-speed rotation of the microfiber 
constituent solution results in high centrifugal forces, and the ensuing solvent evaporation 
generates microfibers.131 More novel methods such as mold based fiber fabrication for study of 
drug release characteristics have been explored recently. One such approach is fabricating 
hollow alginate fibers in a mold composed of a hollow fiber microfiltration membrane.132  
Wet spinning produces microfibers that could form scaffolds with both tissue engineering 
and drug delivery applications. PLLA (poly(L-lactic acid)) and PLGA (poly(lactic-co-glycolic 
acid)) microfibers fabricated by wet spinning were loaded with insulin, lysozyme, and Bovine 
Serum Albumin by means of a cryogenic emulsion technique (Figure 12 (a)).133 The molecular 
weight of insulin, lysozyme, and Bovine Serum Albumin were 5.8 kDa, 14.3 kDa, and 66.0 kDa, 
respectively. It was apparent that the mechanical and drug release rates were highly dependent 
on the molecular weights of the encapsulated proteins for both the fiber types. Lighter 
hydrophilic proteins such as insulin remained encapsulated within the fibers longer (63 days) 
than the heavier molecules. This indicates that smaller therapeutic molecules are more suitable 
for applications such as drug delivery and tissue regeneration, both of which require long term 
sustained delivery of drugs. Loading of BSA in PLGA resulted in a higher tensile strength 
compared to PLLA.  It was concluded from the studythat semi crystalline fibers such as PLLA 
may be suitable for the encapsulation of lighter proteins, whereas amorphous porous microfibers 
composed of PLGA may be better candidates for heavier proteins like BSA. The radius of 
fabricated fibers measured approximately 50 μm. 
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 Lavin et al. demonstrated again that encapsulation of drugs in wetspun microfibers 
increases the mechanical properties of microfibrous scaffolds.134 Hydrophobic anti-inflammatory 
drug Dexamethasone was encapsulated in Poly(l-lactic acid) (PLLA) wetspun fibers. In this 
research, the in vitro drug release kinetics was studied as well as the mechanical properties of the 
fibers. The cross-section of PLLAfiber, shown in Figure 12 (b), had an average diameter of 
64.3±7 µm. It was observed that the drug release profile was long term and linear, releasing 28% 
of the encapsulated drug until the end of 56 days. Additionally, an increase in crystallinity of the 
fibers was observed due to encapsulation. The drug loaded fibers retained 97% of the tensile 
strength present at the outset compared to a control without the drug. It was concluded that 
loading therapeutic molecules less than 600 kDa might have a positive effect on the tensile 
strength of the microfibers.  
 
  
Figure 12 (a) Scanning electron micrographs under 350-time magnification BSA loaded PLGA 
microfibers fabricated by wet spinning.133 (b) Surface and cross sectional features of microfibers 
fabricated by wet spinning. Magnification value for the image is 1300-times.134  
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 In rotary spinning, the fiber morphology is primarily controlled by adjusting the rotary 
speed, polymeric solution composition, and inner diameter of the wall orifices.135 Szabo et al. 
fabricated hydroxypropyl cellulose fibers by rotary spinning, which were subjected to a 
preformulation study. This is a stage in drug development where the morphological and chemical 
properties of a therapeutic substance are characterized.136 This investigation is significant 
because microfiber based orodispersible tablets were prepared for in vitro dissolution 
enhancement. The drug used in the experiment was carvedilol. The orodispersible tablets were 
produced by compressing fibers that were milled, sieved, and mixed with excipients. The 
diameter of the resulting fibers range from 12.6±4.8 µm to 13.5±6.1 µm. The most interesting 
observation in the study was that the drug dissolution rate from the microfiber based formula was 
independent of the pH of the medium. Furthermore, drugs were found to be in an amorphous 
form in the fibers. 
Hollow and solid microfibers can be generated by mold based techniques to possess 
mechanical and morphological properties desired to incorporate drug delivery systems. This 
method was investigated by Yoo et al.132. They managed to use a hollow-fiber microfiltration 
membrane as the mold and to hold the calcium chloride solution which functions as the cross 
linker. The diffusion of calcium ions occurs radially inwards to the lumen resulting in solid fiber 
formation. On the other hand, hollow fiber formation was affected by forcing out un-crosslinked 
alginate from inside the lumen using calcium chloride solution. Figure 13 illustrates the steps by 
which seethe hollow fiber is fabricated. The diameters of the hollow fibers obtained in this 
manner ranged from 200 µm outer diameter (O.D.) and 50 µm inner diameter (I.D.) to 1.42±0.06 
mm O.D. and 0.65±0.004 mm I.D. The outer and inner diameters were varied by changing the 
inner diameter of the mold and cross-linking time, respectively. Due to the ability to exert 
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precise control over morphology and strength, and the fact that the fabrication process does not 
involve high pressures, voltages, or cytotoxic materials, this process is ideal for incorporating 
drug delivery systems into microfibers. Although the method is ideal for small scale fabrication 
of microfiber, mass production of microfibers is not possible with this method. Furthermore, the 
length of the fibers produced is limited to the length of the mold. 
 
 
Figure 13 Mold based technique for fabricating hollow alginate fibers. (a) A vertical sectional 
view of the hollow fiber membrane with CaCl2 solution filling the pores; (b) The lumen of the 
mold being filled with aqueous sodium alginate. (c) Calcium ions diffuse from the pores towards 
the central axis of the lumen resulting in the cross-linking of the alginate. (d) Un-cross-linked 
alginate solution is forced out of the lumen by the CaCl2 solution. (e) The fiber is expelled from 
the mold with water.132  
 
The above discussed applications of wet spun and rotary spun fibers are summarized in 
Table 3. The material composition, drug and target organ/ tissues are indicated. Diameter of the 
cross-section of the fiber is given if provided. 
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Table 3 Details of fibers fabricated by wet spinning and rotary spinning methods for drug 
delivery systems. 
Author Material Drug Target Diameter 
Lavin et 
al.133 
PLLA, 
PLGA 
Insulin, 
Lysozyme, 
BSA 
 
pancreas N/A 
Lavin et 
al.134  
PLLA Dexamethas
one 
Inflamed tissue 64.3±7 µm 
Szabo et 
al.135 
Hydroxy
propyl 
cellulose 
Semisynthet
ic alkaloid 
N/A 12.6±4.8 µm to 
13.5±6.1 µm 
 
5. Self-Assembling fibers: Applications in drug delivery  
The self-assembly of Peptide amphiphile (PA) molecules is triggered by the ionic strength of the 
in vivo environment. This behavior allows the fabrication of nanostructures in the extracellular 
spaces found within numerous tissue structures that constitute the body. Due to the nature of the 
mechanism of self-assembly in fiber formation, self-assembled hydrogel fibers present unique 
qualities that make them ideal for drug delivery. Efficient delivery of drug carriers to 
intercellular compartments is difficult to perform using other fibers fabricated by other methods. 
Additionally, drugs incorporated with self-assembled fibers could be kept in stable in 
intercellular compartments with properties intact. The advantage of using this method is that 
certain drug molecules that cannot be incorporated to fibers by covalent binding, can be 
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physically encapsulated within self-assembled hydrogel fibers.137 Moreover, fibers with a higher 
loading capacity for drugs and efficiency can be fabricated by self-assembly.138 This was 
demonstrated by Zhang et al. in fabricating paclitaxel loaded self-assembled microfibers 
composed of Tat Cell Penetrating Peptide Units.139 The self-assembly of these molecules to 
fibers is schematically depicted in Figure 14. Also demonstrated was the possibility of 
transporting encapsulated drug particles into cells by means of an adsorptive-mediated 
endocytosis pathway. The efficacy of paclitaxel delivered in the fiber, was found to be the same 
as that of free paclitaxel. Therefore, the intrinsic properties of the drug molecule loaded to the 
fibers were kept intact. The main disadvantages of self-assembled fibers include limitations, 
which are a consequence of the size and inability to incorporate certain molecules and structures 
in encapsulated form in self-assembled fibers.  
 
 
Figure 14. Schematic of self-assembly of Tat Cell Penetrating Peptide Units to form nanofibers 
where paclitaxel is encapsulated.139 
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 The nature of self-assembly, to generate nanofibers, makes it an ideal technique to be 
used in other minimally invasive applications as well. PA molecules designed to self-assemble to 
nanofibers were investigated by Shah et al.140 The nanofibers fabricated in this study were 
capable of cartilage regeneration through transforming growth factor β-1 (TGβ-1). This is 
accomplished by displaying a higher density of binding epitopes to the growth factor. The slow 
release of TGβ-1 from such fibers in vitro resulted in an increase in the survival rate and 
chondrogenic differentiation of human mesenchymal stem cells. The material is capable of 
articular cartilage generation regardless of the presence of the exogenous growth factor in a 
rabbit model. This means that the potential for the usage of this material for cartilage 
regeneration activities is significant. The application of self-assembling peptides to generate 
nanofibers capable of creating microenvironments within the myocardium was explored by 
Davis et al.141 The microenvironments capable of promoting vascular smooth muscle cell 
recruitment were generated by injecting designer self-assembling peptide molecules. This 
enabled formation of functional vascular structures, suggesting potential for injectable tissue 
regeneration strategies in the future. In a separate study, Heparin-binding peptide amphiphiles 
were used to generate nanofibers that interact with heparin.142 A significant improvement in 
pancreatic islet engraftment was observed when vascular endothelial growth factor (VEGF) and 
fibroblast growth factor-2 (FGF-2) were delivered from fabricated fibers. Hence, peptide 
amphiphile self-assembly based nanofibers could potentially be used for drug delivery 
applications. In addition, investigations carried out by Nagai et al. on self-assembling peptide 
nanofibers suggested that the release profiles of drugs, which are integrated to hydrogel scaffolds 
composed of self-assembled peptides, could be customized by controlling nanofiber-diffusant 
 51 
 
molecular interactions.143 Single-molecule fluorescence correlation spectroscopy was used to 
study the release kinetics of functional proteins. These proteins span a wide range of molecular 
mass, hydrodynamic radii and isoelectric points, create nanofiber hydrogel scaffold consisting of 
designer self-assembling peptides by Koutsopoulos et al.144 The observations indicated that the 
protein functionality was unaffected by the encapsulation and release from the scaffold, 
demonstrating the suitability of such scaffolds for sustained delivery of drugs in a clinical 
context. Self-assembling peptide scaffolds, integrated with Epidermal Growth Factor, were 
investigated as a method to accelerate wound healing by Schneider et al.145 The scaffold was 
tested on a human skin equivalent model and it was observed that the Epidermal Growth Factor 
was only released when the scaffold was in contact with the tissue model. Furthermore, the 
scaffold demonstrated an accelerated rate of wound healing. The use of Self-Assembling Peptide 
Amphiphile Nanofiber scaffolds for replacement of dental caries with dental stem cells, 
demonstrates the versatility of the technique.146 Instead of replacing decayed dental structures 
with inert materials, scaffolds of this nature could prove to be an effective biological substitute. 
Similarly, electrospun scaffolds of self-assembling peptides hybridized with polyethylene oxide 
have been explored as a viable biomaterial for bone tissue engineering due to the biomimicry of 
self-assembled biological molecules147 
Instances of self-assembled fibers with regard to specific applications are summarized in Table 
4. The material composition and function are given. 
Table 4 Details of fibers fabricated by self-assembly. 
Author Material Function 
Jiang et al.148 laminin, isoleucine-lysine- Promoting neurite outgrowth and inhibit glial 
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valine-alanine-valine Peptide 
amphiphile (IKVAV PA) 
differentiation 
Tysseling-
Mattiace et 
al.149 
IKVAV PA regeneration of both sensory and motor neurons, 
reduction in cell mortality 
Guo et al.150 RADA16-I peptide Reknitting the injured spinal cord 
Shah et al.140 TGFBPA cartilage regeneration 
Davis et al.141 RAD16-II peptide Promote vascular cell recruitment in the 
myocardium. 
Stendahl et 
al.142 
 Heparin-binding peptide 
amphiphiles 
Improvement in pancreatic islet engraftment 
Schneider et 
al.145 
self-complementary peptides 
with 16 amino-acids (RADA16-
I, Ac-
RADARADARADARADA-
CONH2) 
Acceleration of  wound healing 
Galler et al.146 13-amino-acid peptide 
(GTAGLIGQERGDS) 
Dental carrie replacement with dental stem cells 
Brun et al.147 Several peptides with varying 
sequences. 
Applications related to bone tissue engineering 
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6. Conclusion 
Micro and nanofibers are promising candidates for carriers in drug delivery systems. The surface 
area to volume ratio, morphology, material properties, and drug release profile can be easily 
tuned. In this review paper, we showed that electrospinning, microfluidic, wet and dry spinning, 
and self-assembly approaches are commonly used for fabricating fibers applied for drug delivery 
research. All methods are relatively straightforward and feasible under laboratory settings. 
Among these methods, electrospinning was found to be the most prominent approach, and has 
been used extensively to fabricate micro and nanofibers. This method has demonstrated great 
controllability in creating ultrafine fibers, but the limitations in size, shape, biocompatible 
solvent, and process may render it unsuitable for certain applications. The microfluidic platform 
is relatively new with promising potential to fabricate fibers in a variety of dimensions, cross-
section shapes, and biocompatible materials without changing the environmental conditions.  
This makes it a desirable approach for cell incorporation in drug delivery systems. Wet and 
rotary spinning were seen to be less commonly used for generating fibers for drug delivery 
applications. Micro and nanofibers fabricated by these methods have been incorporated with 
stimuli responsive characteristics, such as responsiveness to magnetism and light. Such stimuli 
responsive fibers along with the drug carrying capacity have numerous potential applications in 
drug delivery. Additionally, the incorporation of liposomes with micro and nanofibers were 
shown to enhance the drug carrying capacity in drug delivery systems. The use of self-assembly 
methods for fiber fabrication has proved to be a novel and effective method to create structures 
in the intercellular matrix while encapsulating drugs.  
  For each of these fiber fabrication methods, the constituent molecules are biocompatible. 
Thus, they are viable carriers for drugs in vivo. For example, the incorporation of liposomes into 
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electrospun fibers, utilization of the burst release for HIV prophylaxis, and stimuli responsive 
fibers are all promising prospects for drug delivery applications. A wide range of molecules 
could be delivered by these fibers. Additionally, it is possible to exert precise control over drug 
release profiles from fibers. There is significant potential for fiber based drug delivery systems in 
modern clinical medicine. The above mentioned advantages offered by fiber based delivery 
systems outperform current conventional drug delivery systems.  Methods such as orodispersible 
tablets and vaccines could be incorporated with fiber based drug delivery systems in order to 
improve efficiency of drug delivery. However, the majority of developments detailed in this 
review involve in vitro investigations of efficacy and efficiency of fibrous drug carriers. Before 
clinical trials, in vivo studies must be performed extensively to identify the best candidates for 
drug delivery systems incorporated with fibers. Once extensive in vivo studies are carried out, 
manufacturing processes should be developed to commercialize these drug delivery systems in 
clinical medicine.  
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